AU2006280175B2 - Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection - Google Patents

Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection Download PDF

Info

Publication number
AU2006280175B2
AU2006280175B2 AU2006280175A AU2006280175A AU2006280175B2 AU 2006280175 B2 AU2006280175 B2 AU 2006280175B2 AU 2006280175 A AU2006280175 A AU 2006280175A AU 2006280175 A AU2006280175 A AU 2006280175A AU 2006280175 B2 AU2006280175 B2 AU 2006280175B2
Authority
AU
Australia
Prior art keywords
alkyl
amino
compound
hydrogen
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006280175A
Other languages
English (en)
Other versions
AU2006280175A1 (en
Inventor
Gabor Butora
Kenneth Alan Koeplinger
Malcolm Maccoss
Daniel R. Mcmasters
David B. Olsen
Lihu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp & Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2006280175A1 publication Critical patent/AU2006280175A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK & CO., INC.
Application granted granted Critical
Publication of AU2006280175B2 publication Critical patent/AU2006280175B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2006280175A 2005-08-09 2006-08-04 Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection Ceased AU2006280175B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70670805P 2005-08-09 2005-08-09
US60/706,708 2005-08-09
PCT/US2006/030549 WO2007021610A2 (en) 2005-08-09 2006-08-04 Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection

Publications (2)

Publication Number Publication Date
AU2006280175A1 AU2006280175A1 (en) 2007-02-22
AU2006280175B2 true AU2006280175B2 (en) 2011-09-01

Family

ID=37758066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006280175A Ceased AU2006280175B2 (en) 2005-08-09 2006-08-04 Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection

Country Status (6)

Country Link
US (1) US7632821B2 (enExample)
EP (1) EP1915054A4 (enExample)
JP (1) JP2009513564A (enExample)
AU (1) AU2006280175B2 (enExample)
CA (1) CA2618560A1 (enExample)
WO (1) WO2007021610A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
DK2155758T3 (da) * 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022164941A1 (en) 2021-01-26 2022-08-04 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
US11541071B1 (en) * 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
MX2025013248A (es) * 2023-05-05 2026-02-03 Univ Emory Composiciones terapéuticas de nucleótidos y nucleósidos que contienen 4'-halógeno y usos relacionados con estas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090290A1 (en) * 2002-04-22 2003-10-30 Matsushita Electric Industrial Co., Ltd. Magnetoresistance effect element, magnetic head comprising it, magnetic memory, and magnetic recorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134154A (en) * 1989-10-20 1992-07-28 Merrell Dow Pharmaceuticals Inc. Phenoxy-heterocyclic compounds
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
AU3376699A (en) 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
BR0309581A (pt) * 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090290A1 (en) * 2002-04-22 2003-10-30 Matsushita Electric Industrial Co., Ltd. Magnetoresistance effect element, magnetic head comprising it, magnetic memory, and magnetic recorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Greene, T. W. & Wuts, P. G. M. (1999) "Protective Groups in Organic Synthesis 3rd Edition", John Wiley & Sons, USA, ISBN 0-471-16019-9 *

Also Published As

Publication number Publication date
EP1915054A4 (en) 2010-09-01
EP1915054A2 (en) 2008-04-30
JP2009513564A (ja) 2009-04-02
WO2007021610A3 (en) 2007-10-04
CA2618560A1 (en) 2007-02-22
US20090099126A1 (en) 2009-04-16
US7632821B2 (en) 2009-12-15
WO2007021610A2 (en) 2007-02-22
AU2006280175A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
US7632821B2 (en) Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
AU2005267421B2 (en) Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
AU2007342367B2 (en) Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
EP2120565B1 (en) Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US20120010164A1 (en) Antiviral agents
WO2006065335A2 (en) Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
EP2203463A2 (en) Antiviral agents
EP1987050A2 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
HUP0400726A2 (hu) Nukleozid-származékok, mint az RNS-függő RNS-vírus-polimeráz inhibitorai
EP1758453A2 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired